Novo Nordisk A S Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Novo Nordisk A/S has reported a beneficial ownership of 5.03% in Innate Pharma SA's ordinary shares as of March 31, 2026.
NYSE
Novo Nordisk A/S has reported a beneficial ownership of 7.82% in Innate Pharma SA, holding 7,333,778 ordinary shares.
NYSE
Novo Nordisk A/S has filed an amendment to its Schedule 13G, reporting a 9.65% beneficial ownership stake in Innate Pharma SA.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.2% Passive Stake in Novo Nordisk A/S
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.2% beneficial ownership stake in Novo Nordisk A/S as of March 31, 2025.